A review in JAMA Otolaryngology–Head & Neck Surgery has pulled together what is known about GLP-1 drugs and obstructive sleep apnea, and its bottom line is a qualified one: the drugs work, and they work less well than CPAP. Across six meta-analyses the reduction in the apnea-hypopnea index ran from 5.7 to 21.9 events per … Read more
Metformin and a GLP-1 receptor agonist are one of the most common drug pairings in type 2 diabetes. A case report and literature review published in Kidney360 describes what happens when that combination goes wrong: a 59-year-old woman developed severe metformin-associated lactic acidosis alongside ketoacidosis, while her blood glucose stayed close to normal — the … Read more
A pharmacovigilance study published online in Gut and Liver on 2 September pooled the national adverse-event databases of the United States, Japan and Canada and found gastroesophageal reflux disease reported roughly two to five times more often for GLP-1 drugs than for a comparator diabetes drug class. The signal held in all three countries. It … Read more
A research brief published in Pediatrics on 4 September finds that GLP-1 prescribing to children aged 8 to 11 with obesity rose steeply between 2019 and 2026 while remaining uncommon: across 3,520,531 children in the dataset, 0.6% received a prescription. Every one of those prescriptions was off-label. The three drugs counted are labelled from age … Read more
Eli Lilly announced 52-week results on 31 August 2026 from two Phase 3b trials testing whether adding tirzepatide (Zepbound) to the psoriasis biologic ixekizumab (Taltz) works better than the biologic alone in adults who have psoriatic disease and obesity. It did, on both trials’ primary outcomes and by wide margins. But the primary outcomes were … Read more
A meta-analysis published in Endocrinology, Diabetes & Metabolism in September 2026 puts a number on something patients ask about far more often than they are answered: what happens after you stop. Pooling six studies and 1,776 participants, it estimates weight comes back at 1.04 kg per month, that half of everything lost is back within … Read more
An updated systematic review published in Annals of Internal Medicine on 1 September 2026 pooled 38 randomised trials covering 25,816 adults who had overweight or obesity but not diabetes. It is the cleanest single answer yet to the question most readers arrive with: how much weight does each of these drugs actually take off, above … Read more
A new cohort study adds to a now-consistent finding: people taking semaglutide or tirzepatide are diagnosed with non-scarring hair loss more often than matched non-users. This is not a fringe signal — hair loss is printed on the Wegovy label, among the adverse reactions occurring in at least 2% of treated patients and more often … Read more